DMID 23-0015; Lassa Fever CVD 1000

A Phase 1, Randomized, Recipient- and Observer-Blinded, Dose-Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Two Doses of Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) Administered With 3D-(6-Acyl) PHAD-SE (aPHAD-SE) Adjuvant in Healthy Adults

This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and non-human primates, and then challenged with Lassa virus demonstrated significant protection against Lassa fever. Given that the vaccine backbone is an attenuated and inactivated rabies virus expressing rabies GP, this vaccine will also be evaluated for immunogenicity against rabies virus.

Study Overview

• Status: Active, not recruiting
• Conditions: Lassa Fever
• Intervention / Treatment: Biological: LASSARAB+ aPHAD-SEat 700rU; Biological: HDCV Comparator; Biological: LASSARAB+ aPHAD-SEat 1400rU; Other: Normal Saline Placebo

Detailed Description

Lassa fever is a zoonotic infection endemic in West Africa and is spread by the Lassa virus, an arenavirus causing hemorrhagic fever. Up to 300,000 Lassa fever infections occur annually and while disease is often mild, in a subset of individuals disease is characterized by severe anemia, bleeding, encephalopathy, respiratory failure, shock, and high mortality. In some regions of West Africa, up to 15% of hospital admissions are secondary to Lassa fever, and an estimated 5,000 deaths occur annually. During epidemics of disease, case-fatality rates may reach as high as 50% in hospitalized patients. Approximately one-third of infected individuals will develop hearing loss regardless of disease severity, and in a proportion of patients, permanent deafness occurs.

Prevention of illness through vaccination is a critical goal in reducing the burden of disease from Lassa fever. There are currently no vaccines or therapeutics demonstrated to be efficacious in the prevention or treatment of Lassa fever. This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and non-human primates, and then challenged with Lassa virus demonstrated significant protection against Lassa fever. Given that the vaccine backbone is an attenuated and inactivated rabies virus expressing rabies GP, this vaccine will also be evaluated for immunogenicity against rabies virus.

• Study Type: Interventional
• Enrollment (Estimated): 55
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Provides written informed consent prior to the initiation of any trial procedures.
2. Able to understand and agrees to comply with all planned trial procedures and be available for all study visits.
3. Age ≥ 18 and ≤50 years at time of enrollment.
4. In good general health and without clinically significant medical, psychiatric, chronic or intermittent health conditions including those listed in Exclusion Criteria
5. Participants of childbearing potential must have a negative serum human chronic gonadotropin (HCG) pregnancy test at screening and a negative urine HCG pregnancy test within 24 hours prior to the study vaccination.
6. Participants of childbearing potential in a heterosexual relationship agree to use of highly effective contraception beginning at the time of the screening visit through Day 61 (32 days after the last study treatment).

7. Vital signs and Body Mass Index (BMI) are in the following ranges at screening:

   • Oral temperature is less than 100.4°F (38.0°C).
   • Pulse is 47 to 100 beats per minute, inclusive.
   • Systolic blood pressure (SBP) is 85 to 140 mmHg, inclusive.
   • Diastolic blood pressure(DBP) is 55 to 90 mmHg, inclusive.
   • BMI of 18 kilograms/square meter (kg/m2) (inclusive) to <35 kg/m2
8. Has a negative test result for hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.
9. Has a negative rabies neutralizing antibody test at screening (< 0.5 IU/mL in RFFIT assay)
10. Screening hematology tests (white blood cells, hemoglobin, and platelets) and screening chemistry tests (alanine transaminase, creatine, and total bilirubin) are within acceptable parameters
11. Must agree to the collection and storage of residual biological specimens and additional clinical specimens for secondary research use
12. Agreement to adhere to Lifestyle Considerations during the study

Exclusion Criteria:

1. A history of anaphylaxis, serum sickness, meningitis; neuroparalytic events such as encephalitis, transient paralysis; Guillain-Barré Syndrome; myelitis; retrobulbar neuritis; history of prior or current hearing loss as assessed by quantitative audiometry; or multiple sclerosis
2. Current use of any medications that may be associated with impaired immune responsiveness
3. Allergy treatment with antigen injections within 60 days before first vaccination or that are planned through the end of the study.
4. Receipt of immunoglobulins and/or any blood products within the 60 days before first vaccination or that are planned through the end of the study.
5. Current pregnancy or lactation
6. Known allergic reactions to 1) any rabies vaccine; 2) any components of HDCV (human albumin, neomycin sulfate, phenol red, beta-propiolactone); 3) any components of LASSARAB +aPHAD-SE (LASSARAB, Tris-HCI, L-Arginine, (3D -(6-Acyl) PHAD, Squalene Redistilled, DMPC, Vitamin E Dry Powder).
7. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions to drug or vaccine products.
8. Has a significant acute illness (with or without fever), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to enrollment
9. Receipt of a rabies vaccine or an antibody therapeutic product for treating rabies or a Lassa fever vaccine any time before the first planned study vaccination.
10. Receipt of another experimental agent or intervention within 60 days before first vaccination or plans to do so before the end of the study.
11. Received or plans to receive any other vaccine in the 2 weeks prior to the first vaccination through Day 61 (32 days after the last study treatment).
12. Received or plans to receive any live vaccine in the 4 weeks prior to first vaccination through Day 61 (32 days after the last study treatment).
13. Self-reported or known history of alcoholism within the last 2 years.
14. Any condition that, in the judgment of the investigator, precludes participation because it could affect participant safety or endpoint assessment.
15. Has tattoos, scars, or other marks which would, in the opinion of the investigator, interfere with assessment of the vaccination site.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 - LASSARAB+ aPHAD-SE Vaccine at 700rU or Active Comparator (AC); 4:1 randomization to investigational vaccine or active comparator (n=5)	Biological: LASSARAB+ aPHAD-SEat 700rU; Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection; Biological: HDCV Comparator; Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M; Other Names: Imovax
Experimental: Cohort 2 - LASSARAB+ aPHAD-SE Vaccine at 700rU or 1400rU or AC; 11:4:3 randomization to investigational vaccine dose 700rU or 1400rU or active comparator (n=18)	Biological: LASSARAB+ aPHAD-SEat 700rU; Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection; Biological: HDCV Comparator; Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M; Other Names: Imovax; Biological: LASSARAB+ aPHAD-SEat 1400rU; Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
Experimental: Cohort 3 - LASSARAB+ aPHAD-SE Vaccine at 1400rU Single or Double or AC or AC/Placebo; 11:2:4:1 randomization to investigational vaccine single dose at 1400rU or investigational vaccine (2 doses) at 14rU or active comparator or active comparator and normal saline placebo	Biological: HDCV Comparator; Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M; Other Names: Imovax; Biological: LASSARAB+ aPHAD-SEat 1400rU; Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection; Other: Normal Saline Placebo; Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
Experimental: Cohort 4 - LASSARAB+ aPHAD-SE Vaccine at 1400rU (single) or AC/Placebo; 11:3 randomization to investigational vaccine (2 doses) at 14rU or active comparator and normal saline placebo	Biological: HDCV Comparator; Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M; Other Names: Imovax; Biological: LASSARAB+ aPHAD-SEat 1400rU; Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection; Other: Normal Saline Placebo; Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants experiencing solicited local and systemic events	Number of participants experiencing solicited local and systemic reactogenicity Adverse Events (AEs)	From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable
Percentage of participants experiencing solicited local and systemic events	Percentage of participants experiencing solicited local and systemic reactogenicity Adverse Events (AEs)	From Day 1 through Day 8 for the first vaccination and from Day 29 through Day 36 for the second vaccination, as applicable
Number of participants experiencing unsolicited events	Number of participants experiencing any unsolicited AEs	Day 1 through Day 61
Percentage of participants experiencing unsolicited events	Percentage of participants experiencing any unsolicited AEs	Day 1 through Day 61
Number of participants experiencing Serious Adverse Events (SAEs)	Number of participants experiencing SAEs	Day 1 through Day 394
Percentage of participants experiencing Serious Adverse Events (SAEs)	Percentage of participants experiencing SAEs	Day 1 through Day 394
Number of participants experiencing Medically-Attended Adverse Events (MAAEs)	Number of participants experiencing MAAEs	Day 1 through Day 394
Percentage of participants experiencing Medically-Attended Adverse Events (MAAEs)	Percentage of participants experiencing MAAEs	Day 1 through Day 394
Number of participants experiencing New-Onset Chronic Medical Conditions (NOCMCs)	Number of participants experiencing NOCMCs	Day 1 through Day 394
Percentage of participants experiencing New-Onset Chronic Medical Conditions (NOCMCs)	Percentage of participants experiencing NOCMCs	Day 1 through Day 394
Number of participants experiencing Potential Immune-Mediated Medical Conditions (PIMMCs)	Number of participants experiencing PIMMCs	Day 1 through Day 394
Percentage of participants experiencing Potential Immune-Mediated Medical Conditions (PIMMCs)	Percentage of participants experiencing PIMMCs	Day 1 through Day 394
Number of participants experiencing Adverse Event of Special Interest (AESI)	Number of participants experiencing Adverse Event of Special Interest (AESI) - new onset sensorineural hearing loss (SNHL)	Day 1 through Day 394
Percentage of participants experiencing Adverse Event of Special Interest (AESI)	Percentage of participants experiencing Adverse Event of Special Interest (AESI) - new onset sensorineural hearing loss (SNHL)	Day 1 through Day 394
Number of participants experiencing clinical laboratory AEs	Number of participants experiencing clinical laboratory AEs	Day 1 through Day 61
Percentage of participants experiencing clinical laboratory AEs	Percentage of participants experiencing clinical laboratory AEs	Day 1 through Day 61

Collaborators and Investigators

• Sponsor: Wilbur Chen, MD, MS

Study record dates

Study Major Dates

• Study Start (Actual): January 13, 2025
• Primary Completion (Estimated): May 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: July 30, 2024
• First Submitted That Met QC Criteria: August 7, 2024
• First Posted (Actual): August 9, 2024

Study Record Updates

• Last Update Posted (Actual): June 1, 2026
• Last Update Submitted That Met QC Criteria: May 27, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Lassa
• Additional Relevant MeSH Terms: Infections; RNA Virus Infections; Virus Diseases; Hemorrhagic Fevers, Viral; Arenaviridae Infections; Lassa Fever; Biological Products; Complex Mixtures; Vaccines; Viral Vaccines; Rabies Vaccines
• Other Study ID Numbers: DMID 23-0015

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No